{"id":1289,"date":"2024-01-18T09:28:45","date_gmt":"2024-01-18T09:28:45","guid":{"rendered":"https:\/\/www.the-nash-education-program.com\/?page_id=1289"},"modified":"2024-01-19T09:08:46","modified_gmt":"2024-01-19T09:08:46","slug":"why-treat-nash","status":"publish","type":"page","link":"https:\/\/www.the-nash-education-program.com\/what-is-nash\/why-treat-nash\/","title":{"rendered":"WHY TREAT NASH?"},"content":{"rendered":"\n
Non-alcoholic steatohepatitis patients with fibrosis have a higher risk of progression to cirrhosis, end stage liver disease and hepatocellular carcinoma. Therefore, it is critical to resolve NASH in NASH patients with fibrosis before it has a chance to lead to cirrhosis or cancer, and associated life-threatening outcomes<\/strong><\/strong><\/p>\n\n\n\n NAFLD patients are at higher risk of cardiovascular events. Their atherosclerotic and inflammation markers are\u00a0higher than those of healthy individuals. In fact, cardiovascular disease is the most common cause of death in\u00a0NAFLD patients (38% of cases), before non-liver cancer (19%) and liver-related complications (9%).<\/p>\n\n\n\n <\/p>\n\n\n\n Liver diseases, including complications due to onset of cirrhosis and liver cancer are the third cause of mortality in NAFLD patients after cardiovascular disease and non-liver cancer. Thus, liver transplantation is commonly indicated for NASH patients with end-stage liver disease. But liver transplant is obviously a complex and risky surgical procedure. Besides, it is not always possible to execute due to the lack of donors. Last, patients who would need to undergo liver transplant may not be eligible because other essential body systems may be affected by a deteriorated liver state.<\/p>\n\n\n\n Since no effective medication is currently available to treat the disease, NASH is growing as a major economical and societal issue for many countries. In 2017 for instance, the total cost for a liver transplantation in the United States was estimated at US$812,500 per patient (around 681 000\u20ac) versus US $740,000 in 2014 and US $577,000 in 2011. In Europe, for Italy, France, Germany and the United Kingdom, the total annual cost of NAFLD* patient care is estimated at 35 billion euros per year and could represent an economic burden estimated at 302 billion euros in ten years.<\/p>\n\n\n\n NASH is also associated with higher risk of cardiovascular disease, and is as such increasing global healthcare expenditures and pressure on health systems. Last, NASH provokes irreversible deterioration of quality of life of individuals, ranging from fatigue to more severe clinical symptoms, impacting working individuals and societies\u2019 productivity.<\/p>\n\n\n\n *NAFLD (from NAFL to severe NASH and end-stage liver diseases)<\/p>\n\n\n\nHIGHER CARDIOVASCULAR MORTALITY<\/h2>\n\n\n\n
HIGHER LIVER-RELATED MORTALITY<\/h2>\n\n\n\n
BURDEN FOR SOCIETIES<\/h2>\n\n\n\n